Sanofi Contingent Value Rights
GCVRZ
GCVRZ was delisted on the 3rd of March, 2020.
2 hedge funds and large institutions have $3M invested in Sanofi Contingent Value Rights in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
300,400,000% more capital invested
Capital invested by funds: $1 → $3M (+$3M)
100% more funds holding
Funds holding: 1 → 2 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DMKJ
David M. Knott Jr
|
+$3M |
Top Sellers
GCVRZ Hedge Fund Activity: Q3 2023 in Review
2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q3 2023, worth a combined $3M — up 300,400,000% from $1 a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new GCVRZ positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was David M. Knott Jr, opening a new position worth an estimated $3M.
- 2 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q3 2023, up from 1 in Q2 2023.
- Funds reported $3M of Sanofi Contingent Value Rights stock for Q3 2023, up 300,400,000% quarter-over-quarter.
- 1 fund opened new Sanofi Contingent Value Rights positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest Sanofi Contingent Value Rights buyer in Q3 2023 was David M. Knott Jr, an estimated $3M added.
Based on aggregated 13F filings for Q3 2023.